HLB liver cancer drug fails to win approval again after FDA asks for supplementary data; stock plunges

HLB's liver cancer treatment again ran into an obstacle in the approval process after the US Food and Drug Administration requested supplementary data. In response, 2026 HLB and some affiliates' shares hit the lower limit intraday.7The day10The month

In several reports, the FDA was said to have requested manufacturing-related supplements in addition to clinical data, and cases were reported in which problems at the Chinese partner company's production facilities were cited. The article did not specify any detailed explanation or additional disclosure from the company.

Some article headlines and reports said HLB-related stocks hit the lower limit one after another because of the supplementary request. The repeated description was that many stocks reached trading halts or the lower price limit.

The article-by-article timeline was 2026year 7month 9day and 7month 10day, published as breaking news. The report focuses on the failed approval and the manufacturing partner issue.

Another article addressed concerns over earnings at a distribution-related company. 2026year 7month 9day report said E-Mart's target price was cut by 15%, citing weak Starbucks sales and an expected loss.

Taken together, these reports repeatedly highlighted that the approval review process and manufacturing partner issues were brought into focus at the same time. The articles said the company still has additional disclosures and follow-up measures from regulators ahead.

So far, the reports have focused on the facts at hand: requests for supplementation, production facility issues, and a sharp stock decline. The company's official explanation and the FDA's detailed comment are reflected only to the extent they were specifically stated in the original articles.